Expedite the fight

The shortest path to getting life back to normal now is with early treatment

Donate
We're on a mission to find an existing drug or drug combination that, when given early, reduces hospitalization and fatality rates by 75% or more.
Learn more
The Problem

Nearly all funded clinical trials today are focused on slow or ineffective solutions

1

New drugs/vaccines take a long time to develop and produce and they aren’t effective in every patient.

2

Repurposing existing drugs is much faster. Unfortunately, nearly all clinical trials of repurposed drugs have been conducted via inpatient trials

  • These require participants to be hospitalized before joining the trial

  • Antiviral drugs are most effective when administered early, prior to patients experiencing severe symptoms or hospitalization

3

As a result, inpatient trials have had limited success because patients receive drugs too late

Learn more ›

Our Solution

Identify effective early treatments by funding outpatient clinical trials of the most promising existing drugs

clinical trials ›
Our Solution

Identify early treatments by funding outpatient clinical trials of the most promising existing drugs

Clinical trials ›
Who we are

We are a team of the world’s top scientists, doctors, technologists and philanthropists working, to identify meaningful treatments for COVID-19, that could be used ASAP

Chairman of CETF SAB; immunologist and virologist working on HIV at Johns Hopkins University
Robert Siliciano, M.D., Ph.D.
Johns Hopkins University
Chairman of CETF SAB; immunologist and virologist working on HIV at Johns Hopkins University
Professor of cell biology; virologist and coronavirus expert at Johns Hopkins University
Carolyn Machamer, Ph.D.
Johns Hopkins University
Professor of cell biology; virologist and coronavirus expert at Johns Hopkins University
Professor emeritus of medicine, molecular biology/genetics and
medicine, Johns Hopkins
Stephen Desiderio, M.D, Ph.D.
Johns Hopkins University
Professor emeritus of medicine, molecular biology/genetics and
medicine, Johns Hopkins
Professor emeritus of pathology and medicine; director, University of California, San Diego Center for AIDS Research and Research Center for AIDS and HIV Infection at VA San Diego Healthcare System
Doug Richman, M.D.
University of California
Professor emeritus of pathology and medicine; director, University of California, San Diego Center for AIDS Research and Research Center for AIDS and HIV Infection at VA San Diego Healthcare System
Physician-scientist; HIV clinical trials expert, Harvard Medical School
Raj Gandhi, M.D.
Harvard University
Physician-scientist; HIV clinical trials expert, Harvard Medical School
Professor of medicine (infectious diseases), Howard Taylor Ricketts; HIV virology expert and director, HIV Translational Research Center at Northwestern
Rich D'Aquila, M.D.
Northwestern University
Professor of medicine (infectious diseases), Howard Taylor Ricketts; HIV virology expert and director, HIV Translational Research Center at Northwestern
Full scientific advisory board ›

Who We Are

We are a team of the world’s top scientists, doctors, technologists and philanthropists working, to identify meaningful treatments for COVID-19, that could be used ASAP. Our hand-picked scientific advisory board reviews each credible grant proposal.

full scientific advisory board ›
Robert Siliciano
Immunologist/virologist working on HIV at Johns Hopkins
Carolyn Machamer
Virologist and coronavirus expert at Johns Hopkins
Stephen Desiderio
Professor Emeritus, Immunology and molecular biology, John Hopkins
Richard Whitley
Associate director for drug discovery and development, University of Alabama
Rich D'Aquila
HIV virology and clinical infectious disease expert at Northwestern
Raj Gandhi
Physician scientist, HIV clinical trials expert at Harvard

What medical experts are saying

“I strongly support the work CETF is doing. Testing the top antiviral drugs must be our #1 priority. It is critical to raise funds to enable this testing to take place as soon as possible.”

Siddhartha Mukherjee, MD, PhD

Pulitzer Prize winning author
Researcher & Physician
Columbia University

"It's invigorating to see that CETF is working to fund COVID-19 research in a rapid and collaborative manner and focusing their resources on strategies that are likely to have the greatest immediate impact."

Chetan Bettegowda

Professor of Neurosurgery and Oncology
Johns Hopkins Medical Institutions

"We agree with CETF that preventative approaches have the best chance of alleviating suffering and death from COVID-19 and commend them for supporting these much needed lines of investigation."

Bert Vogelstein

Professor of Oncology
Johns Hopkins Medical Institutions

Donate to the
COVID-19 Early Treatment Fund today
Donate